Adipose tissue as regulator of vascular tone

Current Hypertension Reports

Volumn 14, Issue 3, 2012, Pages 270-278

  Boydens, Charlotte ^a   Maenhaut, Nele ^a   Pauwels, Bart ^a   Decaluwé, Kelly ^a   Van De Voorde, Johan ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Adipokines; Adiponectin; Adipose tissue; Angiotensin II; Apelin; Cardiovascular diseases; Circulating hormones; Hypoxia; Interelukin 6; Leptin; Obesity. Adipocytes; Omentin; Paracrine mediators; Regulator; Resistin; Vascular tone; Vasoactive; Visfatin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ADIPONECTIN RECEPTOR AGONIST; AGENTS AFFECTING PROTEIN METABOLISM; ANGIOTENSIN II; ANGIOTENSINOGEN; APELIN; CELL PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HORMONE; INTERLEUKIN 6; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMENTIN; PERIVASCULAR ADICPOCYTE DERIVED RELAXING FACTOR; RESISTIN; RIMONABANT; TARANABANT; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPONECTIN BLOOD LEVEL; ADIPOSE TISSUE; ANGIOTENSIN BLOOD LEVEL; ANGIOTENSIN II BLOOD LEVEL; AORTA ANEURYSM; APELIN BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DIABETOGENESIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DESIGN; ENDOTHELIAL DYSFUNCTION; ENZYME BLOOD LEVEL; HEART PROTECTION; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOADIPONECTINEMIA; HYPOXEMIA; INFLAMMATION; INSULIN SENSITIVITY; INTERLEUKIN 6 BLOOD LEVEL; INTRAABDOMINAL FAT; LEPTIN BLOOD LEVEL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OMENTIN BLOOD LEVEL; OXIDATIVE STRESS; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; RESISTIN BLOOD LEVEL; SUBCUTANEOUS FAT; TUMOR NECROSIS FACTOR ALPHA BLOOD LEVEL; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ADIPOCYTES; ADIPOKINES; ADIPOSE TISSUE; ANGIOTENSIN II; HUMANS; INFLAMMATION MEDIATORS; MUSCLE, SMOOTH, VASCULAR; OBESITY; VASCULAR DISEASES;

EID: 84865680233     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0259-6     Document Type: Article

References (99)

1. Maenhaut N, Van de Voorde J. Regulation of vascular tone by adipocytes. BMC Med. 2011;9:25.
2. Yiannikouris F, Gupte M, Putnam K, Cassis L. Adipokines and blood pressure control. Curr Opin Nephrol Hypertens. 2010;19 (2):195-200.
3. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? a review article. Dig Dis Sci. 2009;54 (9):1847-56.
4. Achike FI, To NH, Wang H, Kwan CY. Obesity, metabolic syndrome, adipocytes and vascular function: a holistic viewpoint. Clin Exp Pharmacol Physiol. 2011;38(1):1-10.
5. Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am. 2008;37 (3):753-xi. 6. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-7.
6. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92(3):347-55. (Pubitemid 40277057)
7. Rausch ME, Weisberg S, Vardhana P, Tortoriello DV. Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes. 2008;32(3):451-63. (Pubitemid 351414814)
8. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch-Eur J Physiol. 2007;455 (3):479-92. (Pubitemid 47624196)
9. Wood IS, Stezhka T, Trayhurn P. Modulation of adipokine production, glucose uptake and lactate release in human adipocytes by small changes in oxygen tension. Pflugers Arch. 2011;462 (3):469-77. This paper clearly illustrates that even small changes in oxygen availability can lead to changes in release of adipokines. This is very relevant, as such small changes can be expected in growing adipose tissue in the development of obesity.
10. Rutkowski JM, Davis KE, Scherer PE. Mechanisms of obesity and related pathologies: the macro- and microcirculation of adipose tissue. FEBS J. 2009;276(20):5738-46.
11. Zhang L, Ebenezer PJ, Dasuri K, Fernandez-Kim SO, Francis J, Mariappan N, et al. Aging is associated with hypoxia and oxidative stress in adipose tissue: implications for adipose function. Am J Physiol Endocrinol Metab. 2011;301(4):E599-607. This study for the first time demonstrated that hypoxia and oxidative stress occur in adipose tissue during aging, as is the case in obesitas. This might help explain the cardiovascular diseases that develop during aging.
12. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4- 12.
13. Leung YM, Kwan CY. Dual vascular effects of leptin via endothelium: hypothesis and perspective. Chin J Physiol. 2008;51 (1):1-6.
14. Quehenberger P, Exner M, Sunder-Plassmann R, Ruzicka K, Bieglmayer C, Endler G, et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res. 2002;90(6):711-8. (Pubitemid 34640891)
15. Juan CC, Chuang TY, Lien CC, Lin YJ, Huang SW, Kwok CF, et al. Leptin increases endothelin type A receptor levels in vascular smooth muscle cells. Am J Physiol Endocrinol Metab. 2008;294 (3):E481-7. (Pubitemid 351355217)
16. Korda M, Kubant R, Patton S, Malinski T. Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol. 2008;295(4):H1514-21.
17. Zeidan A, Purdham DM, Rajapurohitam V, Javadov S, Chakrabarti S, Karmazyn M. Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II- and endothelin-1-dependent mechanisms and mediates stretch-induced hypertrophy. J Pharmacol Exp Ther. 2005;315(3):1075-84. (Pubitemid 41635393)
18. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, et al. Leptin regulates proinflammatory immune responses. FASEB J. 1998;12(1):57-65. (Pubitemid 28060271)
19. Shankar A, Xiao J. Positive relationship between plasma leptin level and hypertension. Hypertension. 2010;56(4):623-8.
20. Asferg C, Mogelvang R, Flyvbjerg A, Frystyk J, Jensen JS, Marott JL, et al. Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. Am J Hypertens. 2010;23(3):327- 33.
21. Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, et al. Adiponectin in essential hypertension. J Nephrol. 2002;15 (5):507-11. (Pubitemid 35396514)
22. Li FY, Cheng KK, Lam KS, Vanhoutte PM, Xu A. Cross-talk between adipose tissue and vasculature: role of adiponectin. Acta Physiol (Oxf). 2011;203(1):167-80. This paper is a recent excellent review on adiponectin, at present the most clinically relevant adipokine for vasculature.
23. Ohashi K, Ouchi N, Matsuzawa Y. Adiponectin and hypertension. Am J Hypertens. 2011;24(3):263-9.
24. Cao Y, Tao L, Yuan YX, Jiao XY, Lau WB, Wang YJ, et al. Endothelial dysfunction in adiponectin deficiency and its mechanisms involved. J Mol Cell Cardiol. 2009;46(3):413-9.
25. Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes. 1999;48 (4):903-8. (Pubitemid 29153093)
26. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens. 2003;16(1):72-5. (Pubitemid 36078595)
27. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: from obesity to cardiovascular disease. Obes Rev. 2009;10(3):269-79.
28. Shinmura K. Is adiponectin a bystander or a mediator in heart failure? the tangled thread of a good-natured adipokine in aging and cardiovascular disease. Heart Fail Rev. 2010;15(5):457-66.
29. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A, et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension. 2006;47(6):1108-16. (Pubitemid 44289168)
30. Liu S, Yin T, Wei X, Yi W, Qu Y, Liu Y, et al. Downregulation of adiponectin induced by tumor necrosis factor alpha is involved in the aggravation of posttraumatic myocardial ischemia/reperfusion injury. Crit Care Med. 2011;39(8):1935-43.
31. Vaiopoulos AG, Marinou K, Christodoulides C, Koutsilieris M. The role of adiponectin in human vascular physiology. Int J Cardiol. 2011.
32. Olholm J, Paulsen SK, Cullberg KB, Richelsen B, Pedersen SB. Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. Int J Obes (Lond). 2010;34(10):1546-53.
33. Wang T, Qiao S, Lei S, Liu Y, Ng KF, Xu A, et al. Nacetylcysteine and allopurinol synergistically enhance cardiac adiponectin content and reduce myocardial reperfusion injury in diabetic rats. PLoS One. 2011;6(8):e23967.
34. Otvos L, Jr., Haspinger E, La RF, Maspero F, Graziano P, Kovalszky I, et al. Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol. 2011;11:90. In this paper, the development of a first-in-class adiponectin receptor agonist is described, which can lead to innovative drug development for situations requiring replacement of low adiponectin levels in the body.
35. Yamawaki H, Tsubaki N,MukohdaM, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun. 2010;393(4):668-72.
36. Cai RC, Wei L, DI JZ, Yu HY, Bao YQ, Jia WP. Expression of omentin in adipose tissues in obese and type 2 diabetic patients. Zhonghua Yi Xue Za Zhi. 2009;89(6):381-4.
37. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007;56(6):1655-61. (Pubitemid 46842600)
38. Moreno-Navarrete JM, Catalan V, Ortega F, Gomez-Ambrosi J, Ricart W, Fruhbeck G, et al. Circulating omentin concentration increases after weight loss. Nutr Metab. 2010;7.
39. Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res. 2009;81(2):370-80.
40. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatininduced angiogenesis. Cardiovasc Res. 2008;78(2):356-65. (Pubitemid 351556097)
41. Saddi-Rosa P, Oliveira CS, Giuffrida FM, Reis AF. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr. 2010;2:21.
42. Dahl TB, Yndestad A, SkjellandM, Oie E, Dahl A, Michelsen A, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis-Possible role in inflammation and plaque destabilization. Circulation. 2007;115(8):972- 80. (Pubitemid 46328290)
43. Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH, Koo TH, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappa B activation in endothelial cells. Biochim Biophys Acta, Mol Cell Res. 2008;1783(5):886-95.
44. Zhang CH, Hein TW, Wang W, Kuo L. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res. 2003;92(3):322-9. (Pubitemid 36258555)
45. Engeli S, Schling P, Gorzelniak K, BoschmannM, Janke E,Ailhaud G, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol. 2003;35 (6):807-25. (Pubitemid 36379323)
46. Cai H, Li ZM, Dikalov S, Holland SM, Hwang JN, Jo H, et al. NAD(P)H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin. J Biol Chem. 2002;277(50):48311-7. (Pubitemid 35470785)
47. Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag. 2008;4(5):971-81.
48. Thatcher S, Yiannikouris F, Gupte M, Cassis L. The adipose renin-angiotensin system: role in cardiovascular disease. Mol Cell Endocrinol. 2009;302(2):111-7.
49. Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit. 2005;11(5):RA155-62. (Pubitemid 40790953)
50. Ran JM, Hirano T, Fukui T, Saito K, Kageyama H, Okada K, et al. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metab Clin Exp. 2006;55(4):478-88.
51. Skurk T, van Harmelen V, Blum WF, Hauner H. Angiotensin II promotes leptin production in cultured human fat cells by an ERK1/2 dependent pathway. Obes Res. 2005;13(6):969-73.
52. Gentile MT, Vecchione C, Marino G, Aretini A, Di Pardo A, Antenucci G, et al. Resistin impairs insulin-evoked vasodilation. Diabetes. 2008;57(3):577-83.
53. Dick GM, Katz PS, Farias M, Morris M, James J, Knudson JD, et al. Resistin impairs endothelium-dependent dilation to bradykinin, but not acetylcholine, in the coronary circulation. Am J Physiol Heart Circ Physiol. 2006;291(6):H2997-3002. (Pubitemid 44904101)
54. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111(7):932-9. (Pubitemid 40279897)
55. Zhang LX, Curhan GC, Forman JP. Plasma resistin levels associate with risk for hypertension among nondiabetic women. J Am Soc Nephrol. 2010;21(7):1185-91.
56. Brian Jr JE, Faraci FM. Tumor necrosis factor-alpha-induced dilatation of cerebral arterioles. Stroke. 1998;29(2):509-15. (Pubitemid 28086699)
57. Johns DG, Webb RC. TNF-alpha-induced endotheliumindependent vasodilation: a role for phospholipase A2-dependent ceramide signaling. Am J Physiol. 1998;275(5 Pt 2):H1592-8.
58. Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA, et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J. 2004;18(14):1657-69. (Pubitemid 39463705)
59. Zhang HR, Park YJ,Wu JX, Chen XP, Lee S, Yang J, et al. Role of TNF-alpha in vascular dysfunction. Clin Sci. 2009;116(3-4):219- 30.
60. Ohkawa F, Ikeda U, Kawasaki K, Kusano E, Igarashi M, Shimada K. Inhibitory effect of interleukin-6 on vascular smooth muscle contraction. Am J Physiol. 1994;266(3):H898-902.
61. Lee DL, Sturgis LC, Labazi H, Osborne JB, Fleming C, Pollock JS, et al. Angiotensin II hypertension is attenuated in interleukin- 6 knockout mice. Am J Physiol Heart Circ Physiol. 2006;290(3): H935-40.
62. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101 (15):1767-72. (Pubitemid 30213096)
63. Chudek J, Wiecek A. Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep. 2006;58(Suppl):81-8.
64. Langenberg C, Bergstrom J, Scheidt-Nave C, Pfeilschifter J, Barrett-Connor E. Cardiovascular death and the metabolic syndrome- role of adiposity-signaling hormones and inflammatory markers. Diabetes Care. 2006;29(6):1363-9. (Pubitemid 44125936)
65. Schrader LI, Kinzenbaw DA, Johnson AW, Faraci FM, Didion SP. IL-6 deficiency protects against angiotensin II-Induced endothelial dysfunction and hypertrophy. Arterioscler Thromb Vasc Biol. 2007;27(12):2576-81. (Pubitemid 350158908)
66. Klouche M, Bhakdi S, Hemmes M, Rose-John S. Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol. 1999;163(8):4583-9. (Pubitemid 29474529)
67. Salcedo A, Garijo J, Monge L, Fernadez N, Garcia-Villalon AL, Turrion VS, et al. Apelin effects in human splanchnic arteries: role of nitric oxide and prostanoids. Regul Pept. 2007;144(1-3):50-5. (Pubitemid 350030302)
68. Japp AG, Cruden NL, Amer DAB, Li VKY, Goudie EB, Johnston NR, et al. Vascular effects of apelin in vivo in man. J Am Coll Cardiol. 2008;52(11):908-13.
69. Japp AG, Newby DE. The apelin-APJ system in heart failure pathophysiologic relevance and therapeutic potential. Biochem Pharmacol. 2008;75(10):1882-92.
70. Kagiyama S, Fukuhara M, Matsumura K, Lin YZ, Fuji K, Iida M. Central and peripheral cardiovascular actions of apelin in conscious rats. Regul Pept. 2005;125(1-3):55-9. (Pubitemid 39593708)
71. Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A, et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res. 2005;65(1):73-82. (Pubitemid 40038480)
72. Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005;146(4):1764-71. (Pubitemid 40396885)
73. Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest. 2008;118(10):3343-54.
74. Verlohren S, Dubrovska G, Tsang SY, Essin K, Luft FC, Huang Y, et al. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertension. 2004;44(3):271-6. (Pubitemid 39167221)
75. Gao YJ, Lu C, Su LY, Sharma AM, Lee RM. Modulation of vascular function by perivascular adipose tissue: the role of endothelium and hydrogen peroxide. Br J Pharmacol. 2007;151(3):323-31. (Pubitemid 46842669)
76. Maenhaut N, Van de Voorde J. Effect of hypoxia in mice mesenteric arteries surrounded by adipose tissue. Acta Physiol (Oxf). 2011;203(1):235-44.
77. Schleifenbaum J, Kohn C, Voblova N, Dubrovska G, Zavarirskaya O, Gloe T, et al. Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. J Hypertens. 2010;28 (9):1875-82.
78. Gao YJ, Zeng ZH, Teoh K, Sharma AM, Abouzahr L, Cybulsky I, et al. Perivascular adipose tissue modulates vascular function in the human internal thoracic artery. J Thorac Cardiovasc Surg. 2005;130(4):1130-6. (Pubitemid 41427351)
79. Maenhaut N, Boydens C, Van de Voorde J. Hypoxia enhances the relaxing influence of perivascular adipose tissue in isolated mice aorta. Eur J Pharmacol. 2010;641(2-3):207-12.
80. Ardanaz N, Pagano PJ. Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Exp Biol Med. 2006;231(3):237-51. (Pubitemid 43334308)
81. Ketonen J, Shi J, Martonen E, Mervaala E. Periadventitial adipose tissue promotes endothelial dysfunction via oxidative stress in diet-induced obese C57BI/6 mice. Circ J. 2010;74(7):1479-87.
82. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986;320(6061):454-6. (Pubitemid 16097810)
83. Cooper D, Stokes KY, Tailor A, Granger DN. Oxidative stress promotes blood cell-endothelial cell interactions in the microcirculation. Cardiovasc Toxicol. 2002;2(3):165-80. (Pubitemid 37013731)
84. Lee RMKW, Lu C, Su LY, Gao YJ. Endothelium-dependent relaxation factor released by perivascular adipose tissue. J Hypertens. 2009;27(4):782-90.
85. Lu C, Zhao AX, Gao YJ, LeeRM. Modulation of vein function by perivascular adipose tissue. Eur J Pharmacol. 2011;657(1-3):111-6. This study for the first time draws attention to the fact that besides arterial function, venous function can be influenced by PVAT.
86. Fang LP, Zhao J, Chen Y, Ma TM, Xu GH, Tang CS, et al. Hydrogen sulfide derived from periadventitial adipose tissue is a vasodilator. J Hypertens. 2009;27(11):2174-U3.
87. Feng XJ, Chen Y, Zhao J, Tang CS, Jiang ZS, Geng B. Hydrogen sulfide from adipose tissue is a novel insulin resistance regulator. Biochem Biophys Res Commun. 2009;380(1):153-9.
88. Yang GD, Wu LY, Jiang B, Yang W, Qi JS, Cao K, et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science. 2008;322(5901):587-90.
89. Lee YC, Chang HH, Chiang CL, Liu CH, Yeh JI, Chen MF, et al. Role of perivascular adipose tissue-derived methyl palmitate in vascular tone regulation and pathogenesis of hypertension. Circulation. 2011;124(10):1160-71. This study for the first time provides evidence that the enigmatic molecule methyl palmitate may function as a vasorelaxing factor released from perivascular adipocytes, and that its release is blunted in hypertension.
90. Takir S, Uydes-Dogan BS, Ozdemir O. Retina evokes biphasic relaxations in retinal artery unrelated to endothelium, K(V), K (ATP), K(Ca) channels and methyl palmitate. Microvasc Res. 2011;81(3):295-302.
91. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288-95. (Pubitemid 35373562)
92. Eringa EC, Bakker W, Smulders YM, Serne EH, Yudkin JS, Stehouwer CD. Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue. Microcirculation. 2007;14(4-5):389-402. (Pubitemid 47050030)
93. Lu C, Su LY, Lee RM, Gao YJ. Mechanisms for perivascular adipose tissue-mediated potentiation of vascular contraction to perivascular neuronal stimulation: the role of adipocyte-derived angiotensin II. Eur J Pharmacol. 2010;634(1-3):107-12.
94. Lu C, Su LY, Lee RM, Gao YJ. Alterations in perivascular adipose tissue structure and function in hypertension. Eur J Pharmacol. 2011;656(1-3):68-73. This study draws attention to the fact that impaired relaxing influence of PVAT in hypertension is associated with a change in composition of the adipocyte and not with the mass of adipocytes.
95. Gao YJ, Holloway AC, Zeng ZH, Lim GE, Petrik JJ, Foster WG, et al. Prenatal exposure to nicotine causes postnatal obesity and altered perivascular adipose tissue function. Obes Res. 2005;13 (4):687-92.
96. Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska M, et al. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation. 2009;119(12):1661-70.
97. Rebolledo A, Rebolledo OR, Marra CA, Garcia ME, Roldan Palomo AR, Rimorini L, et al. Early alterations in vascular contractility associated to changes in fatty acid composition and oxidative stress markers in perivascular adipose tissue. Cardiovasc Diabetol. 2010;9(1):65.
98. Withers SB, Agabiti-Rosei C, LivingstoneDM, LittleMC, Aslam R,Malik RA, et al.Macrophage activation is responsible for loss of anticontractile function in inflamed perivascular fat. Arterioscler Thromb Vasc Biol. 2011;31(4):908-13. This paper provides evidence that loss of anticontractile function in inflamed perivascular fat is due to the presence of activated macrophages in the PVAT.
99. Ouwens DM, Sell H, Greulich S, Eckel J. The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease. J Cell Mol Med. 2010;14(9):2223-34.